Discover the future of pain management on this episode of Atomic Anesthesia as we explore a major breakthrough: the FDA approval of suzetrigine, a first-in-class, nonopioid pain medication. Guided by cutting-edge research and expert editorial insight from Anesthesiology, we dig into how suzetrigine works—targeting the NaV1.8 sodium channel in peripheral nerves—and what this means for patients and providers facing acute pain. You’ll hear about the pivotal NAVIGATE clinical trials, real-world patient experiences, and the medication’s advantages over traditional opioids, including fewer side effects and no risk of addiction. Whether you’re a healthcare professional, patient, or someone passionate about medical innovation, join us to learn how suzetrigine is poised to reshape pain relief and help bridge the gap left by the opioid crisis.

References:

• Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21. PMID: 40117446; PMCID: PMC12061372.
• Rathmell JP, Clark JD, Eisenach JC. Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain. Anesthesiology. 2025 Jun 1;142(6):989-991. doi: 10.1097/ALN.0000000000005465. Epub 2025 May 13. PMID: 40358331.

🎉 FREE RESOURCES:

[FREE DOWNLOAD] FOR THE SRNA: GRAB YOUR FREE SEE/NCE STUDY PLAN HERE

[FREE DOWNLOAD] FOR THE RN: GRAB YOUR FREE ICU DRUG CHART HERE

Check out our other free resources at AtomicAnesthesia.com

⚛️ TOOLS YOU MIGHT LIKE:

🫀Cardiac Pharmacology Course

💉Our popular Triple Badge Buddy & other swag here

⚛️ CONNECT:

🩷 Subscribe to our YouTube channel

💜 Follow us on Instagram

💙Follow us on TikTok

📥 Have a topic you want to hear? Email Professor T at rhea@atomicanesthesia.com